Fate Therapeutics Inc (FATE) shareholders
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3016% above fair value
$1.28−0.06 (-4.48%)
Close on Nov 13, 2026Market cap $153.37MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
59.9%
72M of 120M shares
Institutional holders
155
31 new, 30 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
0 buys · 7 sales
Net sold $336.39K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Jeremy C. Green Joint filing with Redmile Group, LLC (14.99%), RedCo II Offshore SPV LLC (8.12%) and 1 more | 19,164,572 | 14.99% | 13D (active) amendment | Nov 5, 2026 |
| Redmile Group, LLC Joint filing with Jeremy C. Green (14.90%), RedCo II Offshore SPV LLC (8.50%) | 18,229,078 | 14.90% | 13D (active) amendment | Apr 20, 2026 |
| Goldman Sachs & Co. LLC Joint filing with The Goldman Sachs Group, Inc. (7.40%) | 8,487,220 | 7.40% | 13G (passive) | Mar 31, 2025 |
| Boxer Capital, LLC Joint filing with Boxer Asser Management Inc. (6.30%), Joe Lewis (6.30%) | 6,171,000 | 6.30% | 13G (passive) | Jan 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FATE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Redmile Group, LLC | 12,872,946 | 10.74% | $34.76M | – | 2.33% |
| BlackRock, Inc. | 7,298,895 | 6.09% | $19.71M | −2,769,719 | 0.00% |
| Vanguard Portfolio Management LLC | 4,545,893 | 3.79% | $12.27M | +411,308 | 0.00% |
| Vanguard Capital Management LLC | 4,445,536 | 3.71% | $12.00M | +253,473 | 0.00% |
| Acadian Asset Management LLC | 4,351,250 | 3.63% | $11.74M | +231,050 | 0.01% |
| Aqr Capital Management LLC | 3,837,229 | 3.20% | $10.36M | +835,708 | 0.00% |
| Two Sigma Investments, LP | 3,589,863 | 3.00% | $9.69M | +123,077 | 0.01% |
| Johnson & Johnson | 3,379,064 | 2.82% | $9.12M | – | 1.14% |
| Renaissance Technologies LLC | 2,983,268 | 2.49% | $8.05M | +8,585 | 0.01% |
| Millennium Management LLC | 2,433,978 | 2.03% | $6.57M | New | 0.00% |
| Goldman Sachs Group Inc | 2,049,187 | 1.71% | $5.53M | +721,430 | 0.00% |
| Geode Capital Management, LLC | 1,322,013 | 1.10% | $3.57M | −1,268,416 | 0.00% |
| T. Rowe Price Investment Management, Inc. | 1,080,320 | 0.90% | $2.92M | New | 0.00% |
| Jane Street Group, LLC | 1,027,007 | 0.86% | $2.77M | +380,028 | 0.00% |
| Citadel Advisors LLC | 993,308 | 0.83% | $2.68M | +50,382 | 0.00% |
| Bruce & Co., Inc. | 989,188 | 0.83% | $2.67M | +200,000 | 0.72% |
| Morgan Stanley | 694,580 | 0.58% | $1.88M | −73,168 | 0.00% |
| Vanguard Fiduciary Trust Co | 640,428 | 0.53% | $1.73M | −13,333 | 0.00% |
| Charles Schwab Investment Management Inc | 610,949 | 0.51% | $1.65M | −145,324 | 0.00% |
| UBS Group AG | 590,178 | 0.49% | $1.59M | −1,231,537 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 155 | 72M | 59.9% | 31 / 59 | 35 / 30 | 12M | 14M |
| Q1 2026 | 158 | 74M | 61.8% | 28 / 55 | 34 / 15 | 19M | 8M |
| Q4 2025 | 146 | 72M | 60.3% | 21 / 32 | 53 / 17 | 7M | 15M |
| Q3 2025 | 143 | 81M | 67.3% | 23 / 44 | 38 / 17 | 15M | 14M |
| Q2 2025 | 139 | 80M | 66.6% | 28 / 44 | 41 / 21 | 4M | 21M |
| Q1 2025 | 132 | 97M | 80.6% | 18 / 40 | 40 / 42 | 17M | 21M |
| Q4 2024 | 159 | 102M | 84.9% | 35 / 45 | 47 / 40 | 13M | 28M |
| Q3 2024 | 164 | 117M | 97.3% | 21 / 42 | 59 / 36 | 17M | 14M |
| Q2 2024 | 182 | 124M | 100.0% | 38 / 56 | 50 / 22 | 17M | 24M |
| Q1 2024 | 167 | 131M | 100.0% | 41 / 48 | 52 / 31 | 53M | 20M |
| Q4 2023 | 159 | 99M | 82.5% | 28 / 43 | 58 / 37 | 18M | 15M |
| Q3 2023 | 170 | 95M | 79.7% | 20 / 59 | 56 / 36 | 10M | 22M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
119 funds held FATE in Q1 2026, 51% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of FATE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,194,411 | 2.67% | $8.62M | 0.00% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 2,962,683 | 2.47% | $8.00M | 0.07% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,149,276 | 0.96% | $3.10M | 0.00% | Jun 30, 2026 |
| Bruce Fund | 989,188 | 0.83% | $2.67M | 0.71% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 876,106 | 0.73% | $2.49M | 0.05% | May 29, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 786,810 | 0.66% | $2.12M | 0.07% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 629,759 | 0.53% | $1.70M | 0.02% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 559,342 | 0.47% | $1.59M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 535,817 | 0.45% | $1.52M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 507,444 | 0.42% | $1.44M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 378,180 | 0.32% | $1.02M | 0.07% | Jun 30, 2026 |
| Vanguard Market Neutral Fund | 308,409 | 0.26% | $832.70K | 0.14% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 292,658 | 0.24% | $831.15K | 0.00% | May 31, 2026 |
| AQR Small Cap Multi-Style Fund | 256,360 | 0.21% | $692.17K | 0.18% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Growth Fund | 233,942 | 0.20% | $631.64K | 0.08% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bahram Valamehr | President and CEO, Director | 591,815 | 0.49% | Aug 5, 2026 |
| Kamal Adawi | Chief Financial Officer | 93,418 | 0.08% | Nov 4, 2026 |
| Cindy Tahl | See Remarks | 589,355 | 0.49% | Aug 5, 2026 |
| Jerome Charles Bressi | See Remarks | 335,203 | 0.28% | Jan 16, 2025 |
| William H. Rastetter | Director | 642,424 | 0.54% | Jun 15, 2026 |
| Robert S. Epstein | Director | 36,331 | 0.03% | Jun 15, 2026 |
| Michael Stewart Lee | Director | 11,331 | 0.01% | Jun 15, 2026 |
| Karin Jooss | Director | 9,848 | 0.01% | Jun 15, 2026 |
| Shefali Agarwal | Director | 10,490 | 0.01% | Jun 15, 2026 |
| Yuan Xu | Director | 8,669 | 0.01% | Jun 15, 2026 |
| Redmile Group, LLC | Director, 10% owner | 13,135,758 | 10.96% | Jun 15, 2026 |
| Jeremy Green | Director, 10% owner | 12,884,277 | 10.75% | Jun 15, 2026 |
| Matt Abernethy | Director | – | – | Jun 15, 2026 |
| Laura Hamill | Director | – | – | Jun 15, 2026 |
| RedCo II Master Fund, L.P. | Director, 10% owner | 8,977,624 | 7.49% | Apr 23, 2026 |
| Neelufar Mozaffarian | Director | – | – | May 30, 2025 |
| John Mendlein | Director | 311,231 | 0.26% | May 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kamal Adawi Chief Financial Officer | Nov 3, 2026 | Sale | −6,582 | $2.05 | $13.52K | 93,418 |
| Cindy Tahl See Remarks | Aug 4, 2026 | Sale | −38,800 | $2.46 | $95.45K | 589,355 |
| Bahram Valamehr President and CEO, Director | Aug 4, 2026 | Sale | −43,947 | $2.46 | $108.11K | 591,815 |
| Bahram Valamehr President and CEO, Director | May 20, 2026 | Sale | −28,946 | $1.88 | $54.42K | 635,762 |
| Cindy Tahl See Remarks | May 20, 2026 | Sale | −25,590 | $1.88 | $48.11K | 628,155 |
| Cindy Tahl See Remarks | May 6, 2026 | Option exercise | +44,444 | $1.05 | $46.67K | 653,745 |
| Cindy Tahl See Remarks | May 6, 2026 | Option exercise | +122,220 | $1.32 | $161.33K | 609,301 |
| William H. Rastetter Director | May 5, 2026 | Option exercise | +25,000 | $1.69 | $42.25K | 36,331 |
| Robert S. Epstein Director | May 5, 2026 | Option exercise | +25,000 | $1.69 | $42.25K | 36,331 |
| Jeremy Green Director, 10% owner | Apr 20, 2026 | Other | −8,977,624 | – | – | 0 |
| Jeremy Green Director, 10% owner | Apr 20, 2026 | Other | +8,977,624 | – | – | 12,884,277 |
| Cindy Tahl See Remarks | Jan 15, 2026 | Award | +100,000 | – | – | 487,081 |
| Bahram Valamehr President and CEO, Director | Jan 15, 2026 | Award | +335,000 | – | – | 664,708 |
| Kamal Adawi Chief Financial Officer | Jan 15, 2026 | Award | +25,000 | – | – | 100,000 |
| Cindy Tahl See Remarks | Jan 9, 2026 | Sale | −10,589 | $1.06 | $11.22K | 387,081 |
| Bahram Valamehr President and CEO, Director | Jan 9, 2026 | Sale | −5,190 | $1.07 | $5.55K | 329,708 |
| Kamal Adawi Chief Financial Officer | Oct 20, 2025 | Award | +75,000 | – | – | 75,000 |
| Cindy Tahl See Remarks | Aug 4, 2025 | Sale | −9,037 | $1.06 | $9.58K | 397,670 |
| Bahram Valamehr President and CEO, Director | Aug 4, 2025 | Sale | −14,466 | $1.06 | $15.33K | 334,898 |
| Cindy Tahl See Remarks | Jan 15, 2025 | Award | +70,000 | – | – | 406,707 |
| Jerome Charles Bressi See Remarks | Jan 15, 2025 | Award | +65,000 | – | – | 335,203 |
| Cindy Tahl See Remarks | Jan 10, 2025 | Sale | −5,654 | $1.55 | $8.76K | 336,707 |
| Jerome Charles Bressi See Remarks | Jan 10, 2025 | Sale | −5,980 | $1.55 | $9.27K | 270,203 |
| Bahram Valamehr President and CEO, Director | Jan 10, 2025 | Sale | −8,705 | $1.54 | $13.41K | 349,364 |
| Jeremy Green Director, 10% owner | Dec 20, 2024 | Buy | +397,964 | $1.68 | $668.58K | 12,884,277 |
| Jeremy Green Director, 10% owner | Dec 20, 2024 | Other | −1,084,936 | $1.68 | $1.82M | 11,743,010 |
| Jeremy Green Director, 10% owner | Dec 20, 2024 | Other | +1,084,936 | $1.68 | $1.82M | 12,827,946 |
| Jeremy Green Director, 10% owner | Dec 20, 2024 | Sale | −341,633 | $1.68 | $573.94K | 12,486,313 |
| Jeremy Green Director, 10% owner | Dec 12, 2024 | Conversion | +30,110 | – | – | 12,827,946 |
| Yuan Xu Director | Aug 6, 2024 | Sale(10b5-1 plan) | −633 | $4.23 | $2.68K | 8,669 |
| Cindy Tahl General Counsel and Secretary | Jul 29, 2024 | Award | +200,000 | – | – | 342,361 |
| Bahram Valamehr Chief R&D Officer | Jul 29, 2024 | Award | +200,000 | – | – | 358,069 |
| Edward J. Dulac III Chief Financial Officer | Mar 4, 2024 | Sale(10b5-1 plan) | −2,447 | $7.77 | $19.01K | 101,479 |
| Edward J. Dulac III Chief Financial Officer | Jan 29, 2024 | Sale(10b5-1 plan) | −1,849 | $5.00 | $9.25K | 103,926 |
| Cindy Tahl General Counsel and Secretary | Jan 9, 2024 | Sale | −10,874 | $4.37 | $47.52K | 142,361 |
| Bahram Valamehr Chief R&D Officer | Jan 9, 2024 | Sale | −11,271 | $4.38 | $49.37K | 158,069 |
| Edward J. Dulac III Chief Financial Officer | Jan 9, 2024 | Sale | −7,028 | $4.37 | $30.71K | 105,775 |
| J. Scott Wolchko President and CEO, Director | Jan 9, 2024 | Sale | −14,391 | $4.37 | $62.89K | 371,248 |
| Edward J. Dulac III Chief Financial Officer | Jan 2, 2024 | Sale(10b5-1 plan) | −5,182 | $3.66 | $18.97K | 112,803 |
| Redmile Group, LLC Director, 10% owner | Dec 26, 2023 | Other | −1,655,370 | $3.72 | $6.16M | 13,135,758 |
| Redmile Group, LLC Director, 10% owner | Dec 26, 2023 | Other | +1,655,370 | $3.72 | $6.16M | 13,135,758 |
| Redmile Group, LLC Director, 10% owner | Dec 26, 2023 | Buy | +44,630 | $3.72 | $166.02K | 13,180,388 |
| Edward J. Dulac III Chief Financial Officer | Dec 18, 2023 | Sale(10b5-1 plan) | −1,585 | $3.50 | $5.55K | 117,985 |
| Cindy Tahl General Counsel and Secretary | Nov 9, 2023 | Sale(10b5-1 plan) | −24,363 | $2.40 | $58.47K | 153,235 |
| Edward J. Dulac III Chief Financial Officer | Aug 18, 2023 | Sale | −4,718 | $2.80 | $13.21K | 119,570 |
| Yuan Xu Director | Aug 4, 2023 | Sale(10b5-1 plan) | −632 | $3.71 | $2.34K | 9,302 |
| Brian T. Powl Chief Commercial Officer | Jul 5, 2023 | Sale | −3,854 | $4.87 | $18.77K | 41,146 |
| Edward J. Dulac III Chief Financial Officer | Jul 5, 2023 | Sale(10b5-1 plan) | −5,182 | $4.83 | $25.03K | 124,288 |
| Yuan Xu Director | Jun 14, 2023 | Sale(10b5-1 plan) | −3,460 | $5.58 | $19.31K | 9,934 |
| Jeremy Green Director, 10% owner | Apr 21, 2023 | Buy | +256,639 | $6.18 | $1.59M | 13,135,758 |
| Jeremy Green Director, 10% owner | Apr 20, 2023 | Buy | +20,000 | $5.99 | $119.80K | 12,879,119 |
| Yu-Waye Chu Chief Medical Officer | Apr 18, 2023 | Sale(10b5-1 plan) | −2,317 | $6.58 | $15.25K | 140,676 |
| Yu-Waye Chu Chief Medical Officer | Apr 18, 2023 | Sale(10b5-1 plan) | −215 | $6.52 | $1.40K | 142,993 |
| Jeremy Green Director, 10% owner | Apr 14, 2023 | Sale | −302,339 | $5.84 | $1.77M | 12,833,419 |
| Jeremy Green Director, 10% owner | Apr 14, 2023 | Other | −5,492,385 | $5.84 | $32.08M | 12,833,419 |
| Jeremy Green Director, 10% owner | Apr 14, 2023 | Buy | +25,700 | $6.00 | $154.20K | 12,859,119 |
| Jeremy Green Director, 10% owner | Apr 14, 2023 | Other | +5,492,385 | $5.84 | $32.08M | 12,833,419 |
| Jeremy Green Director, 10% owner | Apr 13, 2023 | Conversion | +167,205 | – | – | 13,135,758 |
| John Mendlein Director | Jan 19, 2023 | Option exercise | +28,461 | $1.37 | $38.99K | 311,231 |
| John Mendlein Director | Jan 13, 2023 | Buy | +36,631 | $5.43 | $198.91K | 282,770 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
11.20%
10M shares short
Days to cover
8.3
At 1M shares a day
Change since last report
-6.1%
From 11M shares
Short volume, 20 days
52.9%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Fate Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,625 shares on Aug 25, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kamal Adawi Officer | Nov 3, 2026 | 6,582 | $13.52K | Nov 3, 2026 | Restricted Stock Vesting |
| Cindy Tahl Officer | Aug 4, 2026 | 38,800 | $95.41K | Aug 4, 2026 | Restricted Stock Vesting |
| Bahram Valamehr Officer, Director | Aug 4, 2026 | 43,947 | $108.10K | Aug 4, 2026 | Restricted Stock Vesting |
| Cindy Tahl Officer | May 20, 2026 | 25,590 | $48.08K | May 20, 2026 | Restricted Stock Vesting |
| Bahram Valamehr Officer, Director | May 20, 2026 | 28,946 | $54.48K | May 20, 2026 | Restricted Stock Vesting |
| Cindy Tahl Officer | Jan 9, 2026 | 10,589 | $11.28K | Jan 9, 2026 | Restricted Stock Vesting |
| Bahram Valamehr Officer, Director | Jan 9, 2026 | 5,190 | $5.56K | Jan 9, 2026 | Restricted Stock Vesting |
| John Mendlein Former Director | Dec 29, 2025 | 38,428 | $38.88K | Dec 24, 2025 | Restricted Stock Vesting |
| Cindy Tahl Officer | Aug 4, 2025 | 9,037 | $9.57K | Aug 4, 2025 | Restricted Stock Vesting |
| Bahram Valamehr Officer, Director | Aug 4, 2025 | 14,466 | $15.40K | Aug 4, 2025 | Restricted Stock Vesting |
| J. Scott Wolchko Former Officer and Director | Mar 6, 2025 | 113,178 | $104.88K | Mar 6, 2025 | Restricted Stock Vesting |
| Bahram Valamehr Officer, Director | Jan 10, 2025 | 8,705 | $13.45K | Jan 10, 2025 | Restricted Stock Vesting |
| Cindy Tahl Officer | Jan 10, 2025 | 5,654 | $8.78K | Jan 10, 2025 | Restricted Stock Vesting |
| Jerome Charles Bressi Officer | Jan 10, 2025 | 5,980 | $9.28K | Jan 10, 2025 | Restricted Stock Vesting |
| Redmile Group, LLC Director, 10% Stockholder | Dec 20, 2024 | 341,633 | $567.11K | Dec 20, 2024 | Private Placements from Stockholders |
See a number that looks wrong?